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VimentinPADs (peptidylarginine deiminases) are calcium-dependent enzymes that change protein-bound arginine to cit-
rulline (citrullination/deimination) affecting protein conformation and function. PAD up-regulation following
chick spinal cord injury has been linked to extensive tissue damage and loss of regenerative capability. Having
found that human neural stem cells (hNSCs) expressed PAD2 and PAD3, we studied PAD function in these cells
and investigated PAD3 as a potential target for neuroprotection by mimicking calcium-induced secondary injury
responses.We show that PAD3, rather than PAD2 is amodulator of cell growth/death and that PAD activity is not
associatedwith caspase-3-dependent cell death, but is required for AIF (apoptosis inducing factor)-mediated ap-
optosis. PAD inhibition prevents association of PAD3with AIF andAIF cleavage required for its translocation to the
nucleus. Finally, PAD inhibition also hinders calcium-induced cytoskeleton disassembly and association of PAD3
with vimentin, that we show to be associated also with AIF; together this suggests that PAD-dependent cytoskel-
eton disassembly may play a role in AIF translocation to the nucleus. This is the ﬁrst study highlighting a role of
PAD activity in balancing hNSC survival/death, identifying PAD3 as an important upstream regulator of calcium-
induced apoptosis, which could be targeted to reduce neural loss, and shedding light on the mechanisms
involved.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The importance of citrullination/deimination, the hydrolysis of
protein-bound arginine to citrulline, in several neural pathologies is be-
coming increasingly apparent [1–7]. These include traumatic injury,
hypoxia and neurodegenerative diseases, such as Alzheimer's disease
and multiple sclerosis, where an increase in Ca2+ levels is considered
to play a relevant role in neural tissue loss [8–11].
Citrullination is carried out by a family of calcium-dependent en-
zymes, peptidylarginine deiminases (PADs) that have different tissue
distributions, often overlapping, and are believed to have distinct sub-
strate speciﬁcity [12–17]. PAD activity has been reported in the cyto-
plasm, including mitochondrial and microsomal fractions, as well as in
the nucleus [18]. Among the known PAD substrates are cytoskeletal
proteins and histones [19,20]. PAD2, the ancestral and more widely
expressed PAD, is the main PAD in the central nervous system (CNS),
though expression of other PADs has been reported in various neural
cell types [15,21,22].it, UCL Institute of Child Health,
020 7905 2372; fax: +44 020
. This is an open access article underInhibition of citrullination can reduce disease onset or severity in
mouse models of multiple sclerosis, rheumatoid arthritis and ulcerative
colitis [23–25]. Signiﬁcantly, the PAD inhibitor Cl-amidine reduces neu-
ral damage in a chick spinal cord injury model and in a neonatal mouse
hypoxia model [6,7,26]. In the chick, PAD3 appears to be the main PAD
involved in secondary injury response, that includes increased intracel-
lular Ca2+, leading to apoptosis and consequent neural tissue loss. Dis-
ruption of a known PAD target, vimentin, reduces viability of HEL
cells, an effect inhibited by Ca2+ chelators [27,28]. Ca2+-dependent
cell death is not executed by caspase 3, and translocation to the nucleus
of the mitochondrial protein, apoptosis inducing factor (AIF), mediates
apoptosis in injured brains [29,30]. AIF down-regulation appears to be
neuroprotective; hence effective targeting of this pathway could be
valuable in pathologies involving Ca2+ homeostasis dysregulation ei-
ther during embryonic development or post-natally, such as traumatic
injuries, hypoxia–ischemia and damage to neural precursors caused
by radiotherapy in young brains [7,30–35].
Having ﬁrst established that PAD3 is expressed in the developing
human nervous system and in human neural stem cells, as in the
chick [6], we investigatedwhether this pathwaymaybe a novel key reg-
ulator of human neural cell death/survival focusing on its potential in-
volvement in calcium-induced cell damage. We show that whereas
PAD inhibition signiﬁcantly increases hNSC growth, raising intracellularthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
1163K.P. U et al. / Biochimica et Biophysica Acta 1843 (2014) 1162–1171Ca2+ with thapsigargin increases PAD3 activity and cell death that is
greatly reduced by a PAD inhibitor or PAD3 siRNA. We also show that
thapsigargin-induced death in hNSCs is dependent on AIF, not caspase
3, and that cleavage of AIF, required for its translocation to the nucleus,
is PAD3-dependent. Finally, we show that vimentin becomes associated
with PAD3 upon cytoplasmic Ca2+ increase, that disrupts cytoskeleton
integrity, and that vimentin is also associatedwith AIF, suggesting a pos-
sible role in AIF stabilization in the mitochondria. Altogether our ﬁnd-
ings support a role for human PADs in the regulation of cell death/
survival, identify PAD3 as an upstream regulator of Ca2+-dependent
cell death, and shed light on the pathway(s) involved.
2. Materials and methods
2.1. Cell lines and treatments
Human tissues were supplied by Human Developmental Biology Re-
sources under ethical approval. Human neural stem cell lines (hNSCs)
from either the brain or the spinal cord of embryos between Carnegie
stage (CS) 18 (gestation age 37–42 days) and CS22 (gestational age
54–56 days) were established and grown as previously described [36].
HEK293T (Human Embryonic Kidney 293) cells were grown DMEM–
High Glucose–GlutaMAX (Gibco) supplemented with 10% fetal calf
serum. The PAD inhibitor Cl-amidine [37] was dissolved in phosphate
buffer saline (PBS) and used at different concentrations (0.1–500 μM
ﬁnal concentration). Thapsigargin (Sigma) dissolved in ethanol was
used at different concentrations (1–25 μM ﬁnal concentration). Cells
were treated with Cl-amidine 15min before the addition of thapsigargin.
In some experiments the inhibitory effect of Cl-amidine treatment 15min
after the addition of thapsigargin was also assessed.
2.2. In-situ hybridization
Spinal cords fromhuman embryos at 46 days of gestationwere ﬁxed
in 4% PFA (par-formaldehyde), parafﬁn embedded and sectioned (7 μm
thickness). PAD2 and PAD3 probes were produced by PCR ampliﬁcation
of the regions corresponding to exon 1 and exon 7 of PAD2 and PAD3
cDNAs, and ligation into the pGEMT-Easy vector (Promega). The
pGEMT-Easy vectors containing either the PAD2 or PAD3 insert were
digested with SpeI or NcoI restriction endonuclease and transcribed
using T7 and Sp6 RNA polymerase to produce DIG labeled riboprobes.
In situ hybridizationwas carried out using digoxigenin-labeled ribo-
probes essentially as previously described [38]. In brief, de-waxed sec-
tions digested with proteinase K (20 mg/ml) were re-ﬁxed in 4% PFA
solution, treatedwith 0.1M triethanolamine containing 0.25% acetic an-
hydride and hybridized overnight at 65°°C. After high stringency
washes, the riboprobes were localized using an alkaline phosphatase-
conjugated sheep anti-digoxigenin Fab fragment (Roche) and detected
by incubation in nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl
phosphate (NBT/BCIP, Roche).
2.3. Immunocytochemistry
hNSCs plated on either coverslip or chamber-slides (PAA)were ﬁxed
with either 4% PFA or 100% ice coldmethanol depending on the antigen
to be detected, for 15 and 5 min, respectively. Immunocytochemistry
was carried out at room temperature essentially as previously described
[39]. The primary antibodies usedwere rabbit anti-PAD3 (Covalab), rab-
bit anti-PAD2 (Covalab), rabbit anti-Cleaved Caspase 3 (Cell Signaling),
goat anti-AIF (Santa Cruz), mouse anti-ß3-tubulin (Promega), mouse
anti-vimentin (Dako), and Alexa 568-conjugated anti-Annexin V (Life
Technologies). Filamentous actin was detected with Alexa Fluor 488-
conjugated phalloidin (0.02 unit/μl; Invitrogen). The secondary anti-
bodies were donkey anti-mouse Alexa 488, donkey or goat anti-rabbit
Alexa 488 or 568, and donkey anti-goat Alexa 594 (Life Technology).
Nuclei were counterstained with Hoechst 33258 (2.5 μg/ml ﬁnalconcentration). Stained cells were visualized and digitally scanned
using an Axiophot 2 (Zeiss) with Hamamatsu ORCA-ER digital camera
or by confocal laser scanning microscopy using an LSM 710 (Zeiss).
Image collection and analysis were performed using Openlab (Perkin
Elmer-Improvision) or ImageJ software [40].
2.4. Western blot and immunoprecipitation
Proteins were extracted from either cell pellets or tissues as previ-
ously described [41]. For Western-blot analysis, 20–40 μg of proteins
per lanewere separated by10%or 12%SDS-PAGE and electrotransferred
to nitrocellulose membranes (GE Healthcare) using a TransBlot-SD
(BioRad). The primary antibodies usedwere the same as for immunocy-
tochemistry. The secondary antibodies were: horseradish peroxidase-
conjugated anti-rabbit immunoglobulin IgG (Dako, Denmark; 1:4000)
and anti-mouse immunoglobulin IgM (Serotec, 1: 4000). Bound anti-
bodies were visualized using the ECL Western Blotting reagents
(Amersham Biosciences).
Immunoprecipitation was carried out using the Millipore 17-500
Catch and Release Immunoprecipitation kit according to the
manufacturer's instructions (Upstate). Three hundred to seven hun-
dred microgram of hNSC proteins were immunoprecipitated with
the anti-PAD3 antibody (5 μg), the anti-AIF antibody (2 μg), or the
F95 antibody (10 μg) and the immunoprecipitated fractions ana-
lyzed by Western blotting.
2.5. Assessment of cell growth cell growth and death
The methylene blue (MB) assay was used to carry out cell growth
analysis in 96well plates as previously described [42]. Propidium iodide
(PI, 2 μg/ml ﬁnal concentration; Sigma) staining was used to assess cell
death either in live cultures or in PFA-ﬁxed cells. Nuclei were counter-
stainedwith Hoechst 33258. Stainingwas visualized either using a ﬂuo-
rescent inverted microscope (Olympus 1X71) with a monochrome
ORCA R2 digital camera (Hamamatsu) or as for immunocytochemistry.
2.6. PAD activity assay
The BAEE (Nα-benzoyl-L-arginine ethyl ester; Sigma) colorimetric
assay was used to assess PAD activity in 5 μg (1 μg protein/μl) of protein
extract per sample with minor modiﬁcations from previously described
protocols [43]. The optical density of the colorimetric reaction detecting
citrulline was measured at 490 nm using a microplate reader (Revela-
tion v4.21 Dynex Technologies, Inc). The background (reading at time
point 0) was subtracted from each sample measurement.
2.7. Reverse-transcription-polymerase chain reaction (RT-PCR) and
quantitative real-time polymerase chain reaction (qPCR)
Total RNA was extracted from tissues (for developmental studies at
least three human embryos at each stage of gestation were used) and
cells using TRIzol reagent (Invitrogen), according to manufacturer's in-
struction; MLTV-Reverse Transcriptase (Promega) was used to prepare
cDNA [44]. In reverse transcription-polymerase chain reaction experi-
ments, all cDNAs were ampliﬁed for 35 cycles except for the house-
keeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase;
30 cycles) using the following conditions: 5 min 95 °C, 30 s 95 °C, 30 s
52 °C–68 °C (depending on primers), and 5 min 72 °C and 4 °C. PCR
products were resolved on 1.5% agarose gel. Primer sequences for RT-
PCR and qPCR and ampliﬁcation conditions used are shown in Supple-
mentary Table 1.
2.8. PAD3 overexpression and siRNA knockdown
The pET16b-hPAD3 plasmid [45]was used as a template for PCR am-
pliﬁcation of human PAD3 (PADI3) using forward and reverse primers
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into EGFP-N2 plasmid using these restriction sites. The PAD3 construct
lacking the enzyme active site, ΔPAD3-EGFP, was made by digesting
the PAD3-EGFP plasmid sequentially with Eco53kI restriction endonu-
clease at 37 °C and SmaI restriction endonuclease at 24 °C. Constructs
were sequenced to ensure they contained the correct sequences.
HEK293T and hNSC at 60% conﬂuency were transfected with the
PAD3-EGFP, ΔPADI3-EGFP or EGFP only plasmid using Lipofectamine
LTX (Invitrogen). For siRNA inhibition studies, hNSC cells were
transfected with validated human PADI3 siRNA (s28546), or PADI2
siRNA (s223214), or negative control siRNA 2 (Ambion) at a ﬁnal con-
centration of 250 nM with Lipofectamine LTX. Knockdown efﬁciency
was assessed by RT-qPCR analysis.
2.9. Statistical analysis
Each experiment was performed at least 3 times; each experimental
group was n = 3–6. Statistical signiﬁcance was evaluated by ANOVA
and Student's t-test; p b 0.05 was taken to be signiﬁcant.
3. Results
3.1. PAD2 and PAD3 isozymes are expressed in the developing human
nervous system and in human neural stem cells (hNSCs)
PAD mRNA expression was assessed in the human central nervous
system (CNS), brain and spinal cord, at different developmental stages
(Fig. 1). Only PAD2 and PAD3 were detected in the developing brain
and spinal cord at all developmental stages studied (46, 63 and
70 days of gestation), whereas the developing human liver, which was
used as a control, also expressed PAD1 and PAD4 (Supplementary
Fig. S1A). An increase in the PAD2 and a decrease in the PAD3 transcript
are observedwith development, but both are detected in the brains and
spinal cords at all stages of gestation studied. Analysis of PAD2 and PAD3
expression by in situ hybridization at 46 days of gestation is consistent
with this ﬁnding and shows that PAD3 expression in the developing
human spinal cord is particularly high in the germinal zone (Fig. 2B).
Antibodies to PAD2 and PAD3, that reacted with proteins of theFig. 1.PAD expression in thedevelopinghuman central nervous system(brain and spinal cord) a
spinal cords (right panel) from human embryos at 42, 63 and 70 days of gestation. PAD2 expres
as a positive control for all PADs. Asterisk indicates statistically signiﬁcant differences (p b 0.05)
days of gestation (dg). Scale bars are 200 μm. C) PAD2 and PAD3protein detected byWestern bl
expression is observed.expected molecular size in Western blots (Supplementary Fig. S1B)
were used to assess PAD2 and PAD3 protein expression. Both PAD2
and PAD3 proteins could be detected byWestern blot in the developing
humanbrains and spinal cords at the stages tested, but their levels of ex-
pression were more difﬁcult to quantify given the limited amount of
human material available (Fig. 1C).
PADmRNAexpressionwas then assessed in 4 hNSCs lineswe gener-
ated from embryonic human brain and spinal cord (Fig. 2A). All hNSC
lines expressed PAD2 and PAD3, but were PAD1 and PAD4-negative
(Supplementary Fig. S1A). Immunocytochemistry shows the presence
of PAD2 and PAD3 proteins in both the nucleus and cytoplasm of
hNSCs (Fig. 2B). Although PAD2 is known to be present in the nucleus
[46], this is the ﬁrst time that human PAD3 has been shown to localize
also to the nucleus. Nuclear localization of PAD2 and PAD3 in hNSCs, to-
gether with evidence of Cit-H3 in these cells, and previously reported
detection of the chick PAD3 in nuclear fractions by Western blot,
strengthen mounting evidence that translocation to the nucleus of
these PADs does not require a classical nuclear localization signal, that
is found only in PAD4 [18,47,48].
3.2. PAD inhibition in normal hNSC increases cell growth
We investigated the effect of reducing PAD basal activity on hNSC
behavior by monitoring cell growth at different times following treat-
ment with the PAD inhibitor, Cl-amidine. A signiﬁcant increase in cell
growth was observed in Cl-amidine treated hNSCs at 48 and 96 h,
with 100 μM being the most effective concentration, suggesting a role
for PAD in the modulation of cell growth (Fig. 2C, Supplementary
Fig. S2). Increased hNSC growth could also be induced by PAD3 siRNA,
but neither by scrambled nor PAD2 siRNA (Fig. 2D). These results sug-
gest a role for PAD3 in the modulation of cell growth.
3.3. Cell death and PAD3 expression in hNSCs are induced by increasing
intracellular Ca2+
We then wished to establish whether increasing cytoplasmic Ca2+
in hNSC with thapsigargin induced cell death in hNSCs, and mimickednd inhNSCs. A) Real time RT-PCRanalysis of PAD3 andPAD2 in fetal brains (left panel) and
sion increaseswhile PAD3 expression decreases with development. Human liver was used
. B) PAD2 and PAD3 transcript detected by in situ hybridization in human spinal cord at 46
ot in developing human brain (Br) and spinal cord (SC); no dramatic change in PADprotein
Fig. 2. PADs are expressed in human neural stem cells (hNSCs) and PAD3 inhibition increases hNSC proliferation. A) PAD2 and PAD3 transcript detected by RT-qPCR in hNSC derived from
embryonic brain and spinal cord (SC). B)Detection of PAD2 and PAD3 by immunocytochemistry (red) inhNSCs: both proteins are detected in cytoplasm andnucleus (counterstainedwith
Hoechst dye). Scale bars: 25 μm. All pictures are at the samemagniﬁcation. C) Analysis of cell growth determined by themethylene blue assay after treatment with 100 μMCl-amidine for
24, 48 or 96 h. Cl-amidine signiﬁcantly increases hNSC proliferation as compared to controls at 48 and 96 h. * = p b 0.05, ** = p b 0.01 by ANOVA and Student's t-test. D) Analysis of cell
growth determined by themethylene blue assay after transfectionwith siRNA against PAD2 (siPAD2) and PAD3 (siPAD3) or scrambled siRNA. A signiﬁcant increase in cell growth as com-
pared to controls is observed at 48 h only in cells transfected with siPAD3 (p b 0.05; two-way ANOVA). Error bars indicate SDM; n ≥ 3.
Fig. 3. Cl-amidine treatment reduces dose-dependent cell death induced by thapsigargin
in hNSCs. A) Quantiﬁcation of cell death induced by 5 μM thapsigargin (Thaps) detected
by propidium iodide (PI) staining. The number of PI-positive cells increases upon
thapsigargin treatment and is reduced both by pre-treatment or post-treatment with
100 μM Cl-amidine (Cl-am); n = 8; error bars = s.d.; ** = p b 0.01 by ANOVA and
Student's t-test. B) Cell survival determined by methylene blue assay after 24 hour
treatment with different concentrations of thapsigargin either alone or following
100 μM Cl-amidine treatment (n ≥ 3; error bars = SDM). Cl-amidine treatment signiﬁ-
cantly increases cell survival (p b 0.05; ANOVA).
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jury in the chick spinal cord.
The ability of different concentrations of thapsigargin to induce
hNSC death at 24 h was assessed by propidium iodide (Fig. 3A and Sup-
plementary Fig. S3) and methylene blue assay (Fig. 3B). Reduced hNSC
survival was observed with 5 μM (LD50) thapsigargin and survival
was further decreased by increasing concentrations of the compound
(Fig. 3B). Thapsigargin-induced cell death was signiﬁcantly reduced by
the PAD inhibitor, Cl-amidine. PAD inhibition also greatly reduced cyto-
skeleton disassembly induced by thapsigargin, as assessed by staining
for actin and vimentin (Supplementary Fig. S4). Altogether this suggests
that PAD activation plays an important role in cell homeostasis.
Analysis of PAD expression in thapsigargin-treated hNSC showed
a signiﬁcant increase in PAD3 transcript levels, whereas no change in
PAD2 expression was detected (Fig. 4A). Up-regulation of the PAD3
transcript was paralleled by increased protein citrullination, as
shown by Western blot using an antibody to protein-bound citrul-
line. Consistent with PAD nuclear localization we also observed an
increase in citrullinated histone 3 (Cit-H3). Thapsigargin-induced
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(Fig. 4B). Altogether these data suggest that increased PAD activity
in thapsigargin-treated hNSCs is due to PAD3 rather than PAD2.
3.4. Cell death is increased by overexpressing PAD3 and reduced by
PAD3 inhibition
To further investigate the relative contribution of the PAD isozymes
to thapsigargin-induced cell death, we constructed a PAD3-EGFP plas-
mid and a truncated PAD3-EGFP (ΔPAD3-EGFP) lacking the C-terminal
active site of PAD3 (Fig. 5 andSupplementary Fig. S5).We initially tested
these construct in HEK293T cells. These cells express PAD3 though at
lower levels than hNSCs (Supplementary Fig. S1C). Expression of EGFP
control vector and PAD3-EGFP in HEK293T cells was detected as early
as 6 h after transfection. It increased over 48 h and PAD3-EGFP was
clearly detected by the PAD3 antibody by Western blot, consistent
with EGFP detection in live cells (Fig. 5A). Afterward the number of
PAD3-EGFP-positive cells, unlike ΔPAD3-EGFP-positive cells, decreased
quite rapidly. To ensure that the protein produced by the PAD3-EGFP
plasmid was functional, we assessed PAD activity by the BAEE activity
assay in protein extracts. PAD activity was much higher in PAD3-EGFP
than in ΔPAD3-EGFP and EGFP transfected HEK293T cells, consistent
with an active PAD3, and this activity was reduced by Cl-amidine
(Fig. 5B, C).
We then assessed the effect of PAD3 over-expression in control and
thapsigargin-treated cells. Cell death, as detected by propidium iodide
(PI), was higher in HEK293T cells transfected with PAD3-EGFP than in
untransfected controls. Upon thapsigargin treatment a signiﬁcantly
higher number of PI-positive cells was observed in PAD3-EGFP as com-
pared to thapsigargin-treated untransfected controls (Fig. 5D). At all the
concentrations of thapsigargin tested, cell survival was signiﬁcantly
lower in PAD3-EGFP cells than in cells carrying ΔPAD3-EGFP or EGFP
alone (Fig. 5E).
The effect of PAD over-expression in hNSCs was then assessed in
hNSC. As for HEK293T cells, PAD3-EGFP reduced survival of
thapsigargin-treated cells as compared to cells transfected ΔPAD3-
EGFP, EGFP alone, or untransfected (Fig. 6A). Consistent with this ob-
servation, a signiﬁcantly higher percentage of PAD3-EGFP-positve
cells, versus cells carrying ΔPAD3-EGFP or an empty EGFP vector
control, were annexin-V-positive following thapsigargin treatment
(Fig. 6B). To further conﬁrm that PAD3 rather than PAD2 is theFig. 4. Effect of thapsigargin on PAD expression and citrullination in hNSCs. A) RT-qPCR
analysis of PAD2 and PAD3 transcripts after thapsigargin treatment: note up-regulation
of PAD3, but not PAD2 transcript, in treated cells; * = p b 0.05 by ANOVA and Student's
t-test (n ≥ 3; error bars indicate SDM). B) Western blot analysis of citrullinated proteins
detected by F95 monoclonal antibody and of citrullinated histone H3 (Cit-H3) following
treatment with either Cl-amidine (100 μM) or thapsigargin (5 μM) alone, or both com-
pounds for 24 h. Cl-amidinewas added to the culturemedium 15min before thapsigargin
treatment. Actin was used as a loading control. Note that PAD activation by thapsigargin
results in protein citrullination and this is reduced by the PAD inhibitor, Cl-amidine.mainmediator of thapsigargin-induced death, we assessed the effect
of PAD3 and PAD2 siRNAs (250 nM) on thapsigargin-induced cell
death. Both siRNAs speciﬁcally reduced the levels of their respective
transcripts by at least 50% as compared to scrambled siRNA or con-
trols (Supplementary Fig. S6); PAD2 siRNA did not show any effect
on PAD3 transcript levels, but some effect of PAD3 siRNA on PAD2
levels was observed, though much smaller than that on PAD3. Treat-
ment with PAD3 siRNA rescued thapsigargin-induced cell death, but
no such effect was observed with the highly selective PAD2 siRNA,
(Fig. 6C). Together these results indicate that PAD3 is the main PAD
modulating this response.
3.5. PAD3 is involved in AIF translocation and cytoskeleton disassembly
In order to identify possible mechanisms of PAD3-induced cell
death, we stained thapsigargin-treated cells for cleaved caspase 3 and
AIF. This treatment did not induce caspase 3 activation, whereas
staurosporine treatment did. In contrast, both treatments induced AIF
translocation from the cytoplasm to the nucleus, that was detectable
by 2h, with AIF being largely nuclear at 8h (Fig. 7A, Supplementary
Fig. 7). Therefore we tested the hypothesis that PAD3-induced cellFig. 5. PAD activity is increased in HEK293T cells expressing PAD3-EGFP A) Live images of
cells transfected either with EGFP alone or PAD3-EGFP 40 h after transfection with corre-
sponding nuclear staining and detection of endogenous PAD3 (ePAD3) and PAD3-EGFP
(P3-G) by Western blot in untransfected cells (1), cell transfected with the EGFP plasmid
(2) and cells transfected with PAD3-EGFP. All panels are at the same magniﬁcation. Scale
bar is 50 μm. B) PAD activity in HEK293Twhole cell lysate assessed by the BAEE assay 24 h
after transfection. A signiﬁcant increase (p b 0.05; two-way ANOVA) in PAD activity is ob-
served in HEK293T cell expressing PAD3-EGFP, but not in HEK293T cells expressing the
mutated PAD3-EGFP lacking enzymatic activity (ΔPAD3-EGFP) where activity is as in
untransfected (WT) cells. C) Cl-amidine (10 μM) signiﬁcantly (p b 0.05; two-way
ANOVA) reduces PAD activity in PAD3-EGFP HEK293T cell lysate in the BAEE assay.
D) Cell death determined by propidium iodide (PI) staining 40 h after transfection with
PAD3-EGFP (P3); *= p b 0.05, **= p b 0.01 by Anova and Student's t-test. E) Cell survival
determined by methylene blue assay after 24 hour treatment with thapsigargin. Signiﬁ-
cantly (p b 0.05; two-way ANOVA) higher cell death is observed in PAD3-EGFP cells
than in HEK293T cells transfected with the EGFP, ΔPAD3-EGFP or WT (labels are as in
(B)). Error bars indicate SDM; n ≥ 3.
Fig. 6. PAD3 is the main PAD involved in hNSC cell death. Death/survival of hNSCs treated for 24 h with thapsigargin was determined by the methylene blue assay and staining for the
apoptosis marker annexin V. A) Cell survival is signiﬁcantly (p b 0.05; two-way ANOVA) reduced in hNSCs carrying PAD3-EGFP as compared to cells transfected with PAD3 lacking the
active site (ΔPAD3-EGFP), EGFP alone, or no transfection (WT). B) Example of cells expressing PAD3-EGFP (PAD, green) and Annexin-V (AnV, red) counted for quantiﬁcation (arrows);
note the signiﬁcantly higher percentage of PAD3-EGFP/Annexin-V-positive cells; * = p b 0.05 by ANOVA and Student's t-test. C) Cell survival is signiﬁcantly (p b 0.05; two-way ANOVA)
increased in hNSC transfected with PAD3 but not PAD2 siRNA. Scale bars are 50 μmin B. Error bars indicate SDM; n ≥ 3.
1167K.P. U et al. / Biochimica et Biophysica Acta 1843 (2014) 1162–1171death is mediated through the AIF pathway. As shown in Fig. 7B, trans-
location of AIF from the mitochondria to the nucleus was inhibited in
thapsigargin-treated hNSCs by the PAD inhibitor, Cl-amidine.
We then wished to gain further insight into the mechanisms by
which PAD may regulate cell death. We therefore assessed whether
AIF was associated with PAD3. Immunoprecipitation with the PAD3 an-
tibody showed that AIF co-precipitated with PAD3 only in hNSCs treat-
ed with thapsigargin, though PAD3 was immunoprecipitated under all
conditions tested (Fig. 7C, D). In addition, association of PAD3 with AIF
was largely abolished by Cl-amidine pre-treatment, and so was a
lower size AIF band observed in thapsigargin-treated lysates. We
further assessed the effect of thapsigargin on AIF cleavage by Western
blotting (Fig. 7E). The cleaved form of AIF was indeed present in
thapsigargin treated-cells, but was not detected when PAD activity
was inhibited by Cl-amidine, indicating that PAD activation is required
for the release of AIF from themitochondria. In order to conﬁrm that as-
sociation of PAD3 with AIF resulted in citrullination of this protein, we
investigated whether AIF co-immunoprecipated with the F95 antibody
to citrullinated proteins, and this was found to be the case (Fig. 7F).
Vimentin, a well-known target of PADs, was also immunoprecipated
by F95 (Fig. 7F).
As cytoskeletal protein integrity was affected by thapsigargin
(Supplementary Fig. S4), we also assessed whether vimentin and
actin, like AIF, were immunoprecipitated by PAD3 only in thapsigargin-
treated cells. Thiswas indeed the case, and this associationwas inhibited
by Cl-amidine pre-treatment, that partly restored cytoskeletal organiza-
tion as well as AIF cytoplasmic localization in the thapsigargin-treated
cells (Supplementary Fig. S4, Fig. 7A, C). In these experiments, double
immunostaining for AIF and either vimentin or actin in hNSCs suggested
a possible co-localization of AIF and vimentin particularly in control cells
(Fig 8A–B).We therefore assessedwhether therewas any direct interac-
tion of AIF with the cytoskeleton by AIF immunoprecipitation. Vimentin,
but not actin, was found to be associatedwith AIF (Fig 8C); thismight re-
ﬂect a role of this intermediate ﬁlament in stabilizing AIF in the
mitochondria.4. Discussion
Together, the ﬁndings reported here suggest that ﬁne tuning of PAD
activity is important for hNSC homeostasis, and that modulation of
PAD3 levels/activity plays a role in balancing their growth and death.
This is consistent with PAD3 association with AIF in the presence of cal-
cium. It has been proposed that identiﬁcation and targeting of upstream
regulators of AIF releasewould provide a valuable therapeutic approach.
Our study suggests that PAD3 is such a regulator.4.1. PAD2 and PAD3 are developmentally regulated in the human CNS
We showed that at embryonic stages and early fetal stages of human
CNS development only PAD2 and PAD3 transcripts are detected. This is
consistent with PAD4 localization to the myelin sheath in the human
CNS, a structure that has not yet formed at the developmental stages
that we were able to examine [12]. The overall levels of PAD2 and
PAD3 transcript change in opposite fashion with development, with
the former increasing and the latter decreasing. This parallel previous
observation in the chick embryo where PAD3 in the germinal zone de-
creases with development and is found in a subset of neurones at later
developmental stages.
Expression of PAD3 at early stages of development in the germinal
region may seem counterintuitive given the evidence of PAD3 involve-
ment in the apoptotic pathway. As the human embryo is not a very trac-
tablemodel for functional studies, at this stagewe can only speculate on
the possible functions of PADs in the developing humanCNS. During de-
velopment, dynamic spontaneous Ca2+ transients in the rat ventricular
region have been proposed to play a role in neural progenitor prolifera-
tion, apical nuclearmigration and early differentiation [32,49]. Brief PAD
activation in response to Ca2+ oscillationsmay therefore be required to
modify target proteins involved in some of these processes, but not suf-
ﬁcient for extensive citrullination leading to cell death. This is consistent
with the presence of low levels of citrullinated proteins in untreated
chick embryos and with evidence that an increase in intracellular
Ca2+ lasting at least 10 min is required for AIF translocation leading to
cell death [29]. As we have found that PAD inhibition increases hNSC
growth, one could hypothesize that cyclical PAD activation in response
to physiological Ca2+ transients may contribute to the regulation of
neural progenitor proliferation/differentiation program(s).4.2. PAD3 is the main PAD modulating cell death in hNSCs
Both PAD2 and PAD3 are expressed in hNSCs. However, they are
differently regulated at the transcriptional level: whereas the PAD3
transcript is up-regulated by increased intracellular calcium, PAD2
is not affected. This difference in human PAD2 and PAD3 regulation
by Ca2+ at the transcriptional level in the human cells parallels
that observed in the chick following spinal cord injury, where only
the PAD3 isozyme was found to be up-regulated in a microarray
screen aimed at identifying gene expression changes in response to
injury [6]. Ca2+-induced increase in PAD3 transcript levels in neural
cells is also consistent with regulation of epidermal PAD3 by Ca2+ in
keratinocytes, where extensive analysis of PAD3 transcriptional reg-
ulation has been carried out [50–53].
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in human cells and this is consistentwith the in vivo injury response re-
ported in the chick [6].We have several lines of evidence supporting thehypothesis that PAD3 and not PAD2, which is the other PAD present in
hNSCs, mediates Ca2+-induced cell death. Increased cell death is ob-
served in cells over-expressing PAD3, and PAD3 siRNA can signiﬁcantly
reduce thapsigargin-induced cell death. In contrast, in these experi-
ments PAD2 knockdown does not increase cell survival in treated
cells, clearly suggesting different functions for these two PADs in hNSCs.4.3. PAD3 is a key upstream regulator of AIF-dependent/caspase
3-independent cell death
Thapsigargin is a Ca2+-ATPase inhibitor that increases cytoplasmic
Ca2+ by reducing its up-take into the endoplasmic reticulum stores.
As shown here, thapsigargin induces cell death in hNSCs in a caspase
3-independent manner. In contrast, thapsigargin treatment promotes
translocation of AIF (apoptosis inducing factor) to the nucleus, a path-
way known to be activated by increased intracellular Ca2+. AIF is a mi-
tochondrial intermembrane ﬂavoprotein that plays a vital role in
mitochondrial function in addition to its role in cell death execution,
where, upon translocation from the mitochondria to the nucleus and
binding to DNA, induces chromatin condensation and DNA degradation
[54,55]. AIF-mediated cell death depends on the cell type and nature of
the apoptotic insult, which may determine the mechanisms of AIF re-
lease from themitochondria [56–59]. Signiﬁcantly, AIF has been report-
ed to play a role in neural tissue damage following hypoxia ischemia in
neonates, and there is some evidence of neural damage reduction in the
neonatal hypoxic–ischemic model upon PAD inhibition [7,60].
It has been proposed that the calcium-dependent activation of the
cysteine protease calpain is required to cleave AIF, that is then released
from the mitochondrial membrane [29,61]. We have shown that in
hNSCs, PAD activation is required for AIF cleavage consistent with AIF
co-precipitating with PAD3 in thapsigargin-treated cells and its inhibi-
tion by Cl-amidine. This positions PAD signaling upstreamof AIF release.
It is conceivable that AIF citrullination is required to expose AIF to
calpain as suggested forﬁlaggrin andNSE and thiswill require extensive
investigation [3,62]. Furthermore, vimentin, a well-known PAD target
that we have shown here to become associated with PAD3 when cyto-
plasmic Ca2+ is increased, has also been reported to be cleaved by
calpain and to play a role in cell death [27].
It is tempting to speculate that citrullination of vimentin may play a
role in AIF translocation. Several cytoskeletal proteins are known to be
PAD targets, and in the oocyte PAD6 is required for lattice formation
and regulation of ribosomal component movements [19,63]. Vimentin
is involved in several cellular processes, includingmitochondriamotility
and apoptosis [2,27,64–67]. The role of vimentin association with AIF
has yet to be elucidated, but it is conceivable that vimentin destabiliza-
tion upon citrullination could affect themitochondria facilitating AIF re-
lease from these organelles and its subsequent translocation to the
nucleus. A possible role for PAD3 in regulating translocation of a
mitochondrial-associated protein to the nucleus is also interesting in
the context of recent work showing a role for citrullination in protein
trafﬁcking in the opposite direction, where REF (RNA binding exportFig. 7. PAD3 expression in hNSCsmodulates thapsigargin-induced cell death via AIF trans-
location. A) Effect of staurosporine (Staur) and thapsigargin (Thaps) treatments for 4 h on
caspase 3 activation (cl-Casp3) and AIF translocation to the nucleus assessed by immuno-
cytochemistry and confocal microscopy. Thapsigargin unlike staurosporine does not acti-
vate caspase 3, but both induce AIF translocation. B) Confocal images showing
translocation of AIF to the nucleus in thapsigargin-treated cells. PAD inhibition by Cl-
amidine (Cl-am) blocks AIF translocation. Scale bars in A and B are 25 μm. C) Immunopre-
cipitation of hNSC protein extractwith the PAD3 antibody (Ly: full lysate; Ft:ﬂow through;
w1: wash 1; w3: wash 3; El: eluate). Note that AIF, vimentin (Vim) and actin are co-
immunopreciptated only in thapsigargin-treated cells. D) PAD3 is immunoprecipitated
under all conditions tested; Con: control. E)Westernblot of protein extracted from control,
thapsigargin- or Cl-amidine and thapsigargin-treated hNSC. The cleaved form of AIF (tAIF)
is detected in thapsigargin-treated extracts but not in extract from cells pre-treated with
Cl-amidine. F) Immunoprecipitation of control and thapsigargin-treated hNSC protein
extracts with the anti-citrullinated protein antibofdy, F95: AIF and vimentin are co-
immunoprecipitated only in thapsigargin-treated cells.
Fig. 8. Thapsigargin induces cytoskeletal disorganization in hNSCs that is reduced by PAD inhibition and affects AIF–vimentin association. Confocal images of hNSC stained for actin
(detected by phalloidin, green) and vimentin (green) and AIF (red) 3 h after treatment; nuclei are counterstained with Hoechst dye (blue). Double-labeling for actin or vimentin and
AIF. Scale bars= 25 μm; all images are at the samemagniﬁcation. B) Highmagniﬁcation images showing possible association of vimentin and AIF and disorganization of the cytoskeleton
upon thapsigargin treatment. C) Immunoprecipitation of hNSC protein extract with the AIF antibody (Ly: full lysate; Ft: ﬂow through; w1: wash 1; w3: wash 3; El: eluate). Vimentin but
not actin is co-immunoprecipitated by AIF.
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the mitochondrial surface [1].
Extensive investigation will be required to assess the role of the cy-
toskeleton in AIF translocation and the precise role of PAD in this pro-
cess and in AIF cleavage. Nonetheless, altogether our results clearly
position PAD3 as an early player in the cascade of events leading to
Ca2+ dependent/caspase 3-independent cell death in hNSCs.
Finally, it has been suggested that AIF-mediated neural cell death is of
particular importance in neural tissue and in some tumors [56,58,68]. In-
formation on PAD3 localization in adult human CNS is lacking, but PAD3
mRNA has been detected in the human cerebellum [21]. Therefore it will
be important to establish whether PAD3 expression determines AIF-
mediated cell death restriction to speciﬁc neural cell subpopulations in
pathologies involving increase in intracellular Ca2+. Future studies on
PAD3 expression in normal and pathological human specimen will be
crucial to clarifying the role of this isozyme in neural pathologies.
5. Conclusions
We have shown that human PAD3 (PADI3) is a key player in hNSC
homeostasis, and particularly in caspase 3 independent cell death in-
duced by increased intracellular calcium in hNSCs. This to our knowl-
edge is the ﬁrst study that demonstrates that PAD3 is an upstream
regulator of Ca2+-induced cell death in human neural cells and sheds
some light on the mechanisms involved. Furthermore, it highlights dif-
ferences in the role of PAD2 and PAD3 in hNSCs. Together with ourprevious work in animal injury models, our ﬁndings in a human
model identify PAD3 pathway targeting as a novel approach to reducing
neural tissue loss in human pathologies where increased intracellular
Ca2+ greatly contributes to cell damage, such as traumatic and hypoxic/
ischemic insults to the CNS.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.02.018.
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